Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Interventions

mirabegron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Interventional × Urinary Bladder Neck Obstruction × Clear all
NCT00410514 2014-04-04

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Astellas Pharma Inc

Phase 2 Completed
200 enrolled 24 charts
EndocrineGenitourinary

Urinary Bladder Neck Obstruction, Multiple Endocrine Neoplasia Type 1, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡